

Dear Shareholder,

Annual General Meeting – Letter to Shareholders

ClearVue Technologies Limited (ASX: CPV OTC:CVUEF) (“**ClearVue**” or the “**Company**”) advises that its Annual General Meeting will be held at 2:00PM (AWST) on Friday, 27 November 2026 at 567 Newcastle Street, West Perth WA 6005.

In accordance with Part 1.2AA of the Corporations Act 2001, the Company will only be dispatching physical copies of the Notice of Meeting (“Notice”) to Shareholders who have elected to receive the Notice in physical form. The Notice is being made available to Shareholders electronically and can be viewed and downloaded online from the Company’s website at: <https://investors.clearvuepv.com/>

Your vote is important

The business of the Annual General Meeting affects your shareholding and your vote is important. To vote in person, attend the Annual General Meeting on the date and at the place set out above. To vote by proxy please use one of the following methods:

Online	Lodge the Proxy Form online at https://portal.automic.com.au/investor/home by following the instructions: Log into the Automic website using the holding details as shown on the Proxy Form. Click on ‘View Meetings’ – ‘Vote’. To use the online lodgement facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown on the front of the Proxy Form.
By post	Completing the enclosed Proxy Form and posting it to: Automic, GPO Box 5193, Sydney NSW 2001
By hand	Completing the enclosed Proxy Form and delivering it by hand to: Automic, Level 5, 126 Phillip Street, Sydney NSW 2000
By email	Completing the enclosed Proxy Form and emailing it to: meetings@automicgroup.com.au

Your Proxy instruction must be received not later than 48 hours before the commencement of the Meeting. **Proxy Forms received later than this time will be invalid.**

The Notice is important and should be read in its entirety. If you are in doubt as to the course of action you should follow, you should consult your financial advisor, lawyer, accountant, or other professional adviser.

The Chair intends to vote all open proxies in favour of all resolutions, where permitted.

Yours Faithfully,

Harry Miller

Company Secretary

CLEARVUE TECHNOLOGIES LIMITED
ACN 071 397 487
NOTICE OF ANNUAL GENERAL MEETING

Notice is given that the Meeting will be held at:

TIME: 2:00pm (WST)
DATE: Friday, 27 November 2026
PLACE: 567 Newcastle Street
West Perth WA 6005

The business of the Meeting affects your shareholding and your vote is important.

This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.

The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 4:00pm (WST) on Wednesday, 25 November 2026.

BUSINESS OF THE MEETING

FINANCIAL STATEMENTS AND REPORTS

To receive and consider the annual financial report of the Company for the financial year ended 30 June 2026 together with the declaration of the Directors, the Directors' report, the Remuneration Report and the auditor's report.

1. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT

To consider and, if thought fit, to pass, with or without amendment, the following resolution as a **non-binding resolution**:

"That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company's annual financial report for the financial year ended 30 June 2026."

Note: the vote on this Resolution is advisory only and does not bind the Directors or the Company.

2. RESOLUTION 2 – ELECTION OF DIRECTOR – ANDREW LAU

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purpose of clause 15.4 of the Constitution, Listing Rule 14.4 and for all other purposes, Andrew Lau, a Director who was appointed as an additional Director on 23 March 2026, retires, and being eligible, is elected as a Director."

3. RESOLUTION 3 – ELECTION OF DIRECTOR – REBECCA YANG

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purpose of clause 15.4 of the Constitution, Listing Rule 14.4 and for all other purposes, Rebecca Yang, a Director who was appointed as an additional Director on 16 July 2026, retires, and being eligible, is elected as a Director."

4. RESOLUTION 4 – APPROVAL OF 7.1A MANDATE

To consider and, if thought fit, to pass the following resolution as a **special resolution**:

"That, for the purposes of Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to that number of Equity Securities equal to 10% of the issued capital of the Company at the time of issue, calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and otherwise on the terms and conditions set out in the Explanatory Statement."

5. RESOLUTION 5 – INCREASE IN TOTAL AGGREGATE REMUNERATION FOR NON-EXECUTIVE DIRECTORS

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of clause 15.8 of the Constitution, Listing Rule 10.17 and for all other purposes, Shareholders approve an increase of the total aggregate amount of fees payable to non-executive Directors from \$350,000 per annum to \$450,000 per annum in accordance with the terms and conditions set out in the Explanatory Statement."

6. RESOLUTION 6 – APPROVAL TO ISSUE SHARES UNDER THE DIRECTOR FEE PLAN – THERESA SMITS

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue Shares in lieu of remuneration to Theresa Smits (or her nominee(s)) under the Director Fee Plan on the terms and conditions set out in the Explanatory Statement."

Dated: 22 October 2026

Voting Prohibition Statements

Resolution 1 – Adoption of Remuneration Report	<p>In accordance with sections 250(BD)(2) and 250R, a vote on this Resolution must not be cast:</p> <ul style="list-style-type: none"> (a) by or on behalf of a member of the Key Management Personnel, details of whose remuneration are included in the Remuneration Report or a Closely Related Party of such a member, regardless of the capacity in which the vote is cast; or (b) as a proxy by a member of the Key Management Personnel at the date of the Meeting, or their Closely Related Parties. <p>However, a person (the voter) described above may cast a vote on this Resolution as a proxy if the vote is not cast on behalf of a person described above and either:</p> <ul style="list-style-type: none"> (a) the voter is appointed as a proxy by writing that specifies the way the proxy is to vote on this Resolution; or (b) the voter is the Chair and the appointment of the Chair as proxy: <ul style="list-style-type: none"> (i) does not specify the way the proxy is to vote on this Resolution; and (ii) expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with the remuneration of a member of the Key Management Personnel.
Resolutions 5 and 6 – Increase in Total Aggregate Remuneration for Non-Executive Directors and Approval to Issue Shares under the Director Fee Plan – Theresa Smits	<p>A person appointed as a proxy must not vote, on the basis of that appointment, on these Resolutions if:</p> <ul style="list-style-type: none"> (a) the proxy is either: <ul style="list-style-type: none"> (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and (b) the appointment does not specify the way the proxy is to vote on these Resolutions. <p>However, the above prohibition does not apply if:</p> <ul style="list-style-type: none"> (a) the proxy is the Chair; and (b) the appointment expressly authorises the Chair to exercise the proxy even though these Resolutions are connected directly or indirectly with remuneration of a member of the Key Management Personnel.

Voting Exclusion Statements

In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the Resolution set out below by or on behalf of the following persons:

Resolution 5 – Increase in total aggregate remuneration for non-executive Directors	A Director or an associate of that person or those persons.
Resolution 6 – Approval to Issue Shares under the Director Fee Plan – Theresa Smits	Theresa Smits (or her nominee(s)) or any other person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the employee incentive scheme in question or an associate of that person or those persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- (a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or
- (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - (ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Voting by proxy

To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance with the instructions set out on the Proxy Form.

In accordance with section 249L of the Corporations Act, Shareholders are advised that:

- each Shareholder has a right to appoint a proxy;
- the proxy need not be a Shareholder of the Company; and
- a Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the Shareholder appoints two proxies and the appointment does not specify the proportion or number of the member's votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes.

Shareholders and their proxies should be aware that:

- if proxy holders vote, they must cast all directed proxies as directed; and
- any directed proxies which are not voted will automatically default to the Chair, who must vote the proxies as directed.

Voting in person

To vote in person, attend the Meeting at the time, date and place set out above.

Should you wish to discuss the matters in this Notice please do not hesitate to contact the Company Secretary on 1300 288 664.

EXPLANATORY STATEMENT

This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions.

1. FINANCIAL STATEMENTS AND REPORTS

In accordance with the Corporations Act, the business of the Meeting will include receipt and consideration of the annual financial report of the Company for the financial year ended 30 June 2026 together with the declaration of the Directors, the Directors' report, the Remuneration Report and the auditor's report.

The Company will not provide a hard copy of the Company's annual financial report to Shareholders unless specifically requested to do so. The Company's annual financial report is available on its website at www.clearvuepv.com.

2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT

2.1 General

The Corporations Act requires that at a listed company's annual general meeting, a resolution that the remuneration report to be adopted must be put to the shareholders. However, such a resolution is advisory only and does not bind the company or the directors of the company.

The remuneration report sets out the company's remuneration arrangements for the directors and senior management of the company. The remuneration report is part of the directors' report contained in the annual financial report of the company for a financial year.

The chair of the meeting must allow a reasonable opportunity for its shareholders to ask questions about or make comments on the remuneration report at the annual general meeting.

2.2 Voting consequences

A company is required to put to its shareholders a resolution proposing the calling of another meeting of shareholders to consider the appointment of directors of the company (**Spill Resolution**) if, at consecutive annual general meetings, at least 25% of the votes cast on a remuneration report resolution are voted against adoption of the remuneration report and at the first of those annual general meetings a Spill Resolution was not put to vote. If required, the Spill Resolution must be put to vote at the second of those annual general meetings.

If more than 50% of votes cast are in favour of the Spill Resolution, the company must convene a shareholder meeting (**Spill Meeting**) within 90 days of the second annual general meeting.

All of the directors of the company who were in office when the directors' report (as included in the company's annual financial report for the most recent financial year) was approved, other than the managing director of the company, will cease to hold office immediately before the end of the Spill Meeting but may stand for re-election at the Spill Meeting.

Following the Spill Meeting those persons whose election or re-election as directors of the company is approved will be the directors of the company.

2.3 Previous voting results

At the Company's previous annual general meeting the votes cast against the remuneration report considered at that annual general meeting were less than 25%. Accordingly, the Spill Resolution is not relevant for this Meeting.

3. RESOLUTION 2 – ELECTION OF DIRECTOR – ANDREW LAU

3.1 General

The Constitution allows the Directors to appoint at any time a person to be a Director either to fill a casual vacancy or as an addition to the existing Directors, but only where the total number of Directors does not at any time exceed the maximum number specified by the Constitution. Pursuant to the Constitution and Listing Rule 14.4, any Director so appointed holds office only until the next annual general meeting and is then eligible for election by Shareholders.

Andrew Lau, having been appointed by other Directors on 23 March 2026 in accordance with the Constitution, will retire in accordance with the Constitution and Listing Rule 14.4 and being eligible, seeks election from Shareholders. Further information in relation to Andrew Lau is set out below.

Qualifications, experience and other material directorships	<p>Mr Lau is an experienced engineer and ESG specialist with more than 20 years' experience working across the built environment, sustainability and energy transition sectors throughout the Asia Pacific region. He has advised institutional asset owners, developers, real estate investment trusts and financiers on improving building performance, managing energy risk and delivering long term asset resilience through technology led solutions.</p> <p>Mr Lau's background combines engineering led building design and performance optimisation with expertise in ESG strategy, energy efficiency, renewable energy integration and smart building technologies. His experience includes large scale commercial assets and mission critical infrastructure such as data centres. Mr Lau has completed specialist training and accreditation in building integrated photovoltaics (BIPV) and energy resilient design for data centres. Mr Lau currently leads ESG advisory initiatives for Asia Pacific clients in his executive role with global real estate advisory firm Colliers, working across major markets including Greater China, Japan, Korea, Singapore and South East Asia. Mr Lau does not currently hold any other material directorships.</p>
Term of office	Andrew Lau has served as a Director since 23 March 2026.
Independence	If elected, the Board considers that Andrew Lau will be an independent Director.
Other material information	The Company conducts appropriate checks on the background and experience of candidates before their appointment to the Board. These include checks as to a person's experience, educational qualifications, character, criminal record and bankruptcy history. The Company undertook such checks prior to the appointment of Andrew Lau.
Board recommendation	Having received an acknowledgement from Andrew Lau that he will have sufficient time to fulfil his responsibilities as a Director and having reviewed the performance of Andrew Lau since his appointment to the Board and the skills, knowledge, experience and capabilities required by the Board, the Directors (other than Andrew Lau) recommend that Shareholders vote in favour of this Resolution.

3.2 Technical information required by Listing Rule 14.1A

If this Resolution is passed, Andrew Lau will be elected to the Board as an independent non-executive Director.

If this Resolution is not passed, Andrew Lau will not continue in his role as an independent non-executive Director. The Company may seek nominations or otherwise identify suitably qualified candidates to join the Company. As an additional consequence, this may detract from the Board and Company's ability to execute on its strategic vision.

4. RESOLUTION 3 – ELECTION OF DIRECTOR – REBECCA YANG

4.1 General

The Constitution allows the Directors to appoint at any time a person to be a Director either to fill a casual vacancy or as an addition to the existing Directors, but only where the total number of Directors does not at any time exceed the maximum number specified by the Constitution. Pursuant to the Constitution and Listing Rule 14.4, any Director so appointed holds office only until the next annual general meeting and is then eligible for election by Shareholders.

Rebecca Yang, having been appointed by other Directors on 16 July 2026 in accordance with the Constitution, will retire in accordance with the Constitution and Listing Rule 14.4 and being eligible, seeks election from Shareholders. Further information in relation to Rebecca Yang is set out below.

Qualifications, experience and other material directorships	<p>Professor Yang is Professor and Doreen Thomas Fellow at the University of Melbourne and is internationally recognised as one of Australia's leading experts in building integrated photovoltaics (BIPV), sustainable building technologies and renewable energy integration.</p> <p>Professor Yang's research spans BIPV, net zero buildings, building energy systems, artificial intelligence, digital twins and the integration of renewable energy into the built environment. Through extensive collaboration with industry, government and research organisations, her work has helped bridge the gap between leading research and practical commercial application. Professor Yang also brings international standards leadership in BIPV. Professor Yang does not currently hold any other material directorships.</p>
Term of office	Rebecca Yang has served as a Director since 16 July 2026.
Independence	If elected, the Board considers that Rebecca Yang will be an independent Director.
Other material information	The Company conducts appropriate checks on the background and experience of candidates before their appointment to the Board. These include checks as to a person's experience, educational qualifications, character, criminal record and bankruptcy history. The Company undertook such checks prior to the appointment of Rebecca Yang.
Board recommendation	Having received an acknowledgement from Rebecca Yang that she will have sufficient time to fulfil her responsibilities as a Director and having reviewed the performance of Rebecca Yang since her appointment to the Board and the skills, knowledge, experience and capabilities required by the Board, the Directors (other than Rebecca Yang) recommend that Shareholders vote in favour of this Resolution.

4.2 Technical information required by Listing Rule 14.1A

If this Resolution is passed, Rebecca Yang will be elected to the Board as an independent non-executive Director.

If this Resolution is not passed, Rebecca Yang will not continue in her role as an independent non-executive Director. The Company may seek nominations or otherwise identify suitably qualified candidates to join the Company. As an additional consequence, this may detract from the Board and Company's ability to execute on its strategic vision.

5. RESOLUTION 4 – APPROVAL OF 7.1A MANDATE

5.1 General

This Resolution seeks Shareholder approval by way of special resolution for the Company to have the additional 10% placement capacity provided for in Listing Rule 7.1A to issue Equity Securities without Shareholder approval.

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary shares it had on issue at the start of that period.

Under Listing Rule 7.1A, an Eligible Entity may seek shareholder approval by way of a special resolution passed at its annual general meeting to increase this 15% limit by an extra 10% to 25% (**7.1A Mandate**). An Eligible Entity means an entity which is not included in the S&P/ASX 300 Index and has a market capitalisation of \$300,000,000 or less. As of the date of this Notice, the Company's market capitalisation is approximately \$18,967,292 (based on 364,755,606 Shares on issue and the closing price of Shares on ASX on 22 October 2026 of \$0.052). The Company is therefore an Eligible Entity.

5.2 Technical information required by Listing Rule 14.1A

For this Resolution to be passed, at least 75% of votes cast by Shareholders present and eligible to vote at the Meeting must be cast in favour of the Resolution.

If this Resolution is passed, the Company will be able to issue Equity Securities up to the combined 25% limit in Listing Rules 7.1 and 7.1A without any further Shareholder approval.

If this Resolution is not passed, the Company will not be able to access the additional 10% capacity to issue Equity Securities without Shareholder approval under Listing Rule 7.1A and will remain subject to the 15% limit on issuing Equity Securities without Shareholder approval set out in Listing Rule 7.1.

5.3 Technical information required by Listing Rule 7.3A

REQUIRED INFORMATION	DETAILS
Period for which the 7.1A Mandate is valid	<p>The 7.1A Mandate will commence on the date of the Meeting and expire on the first to occur of the following:</p> <ul style="list-style-type: none">(a) the date that is 12 months after the date of this Meeting;(b) the time and date of the Company's next annual general meeting; and(c) the time and date of approval by Shareholders of any transaction under Listing Rule 11.1.2 (a significant change in the nature or scale of activities) or Listing Rule 11.2 (disposal of the main undertaking).
Minimum price	<p>Any Equity Securities issued under the 7.1A Mandate must be in an existing quoted class of Equity Securities and be issued for cash consideration at a minimum price of 75% of the volume weighted average price of Equity Securities in that class, calculated over the 15 trading days on which trades in that class were recorded immediately before:</p> <ul style="list-style-type: none">(a) the date on which the price at which the Equity Securities are to be issued is agreed by the entity and the recipient of the Equity Securities; or(b) if the Equity Securities are not issued within 10 trading days of the date in paragraph (a) above, the date on which the Equity Securities are issued.

REQUIRED INFORMATION	DETAILS																																							
Use of funds	<p>The Company intends to use funds raised from issues of Equity Securities under the 7.1A Mandate for the commercialisation of the Company's solar glass and building integrated photovoltaic (BIPV) solutions in key global markets, research and development, continued development of the Company's technology, patents and patent renewals, systems and inventory to support global sales, sales and marketing expenses, general operational expenses and working capital.</p>																																							
Risk of economic and voting dilution	<p>Any issue of Equity Securities under the 7.1A Mandate will dilute the interests of Shareholders who do not receive any Shares under the issue.</p> <p>If this Resolution is approved by Shareholders and the Company issues the maximum number of Equity Securities available under the 7.1A Mandate, the economic and voting dilution of existing Shares would be as shown in the table below.</p> <p>The table below shows the dilution of existing Shareholders calculated in accordance with the formula outlined in Listing Rule 7.1A.2, on the basis of the closing market price of Shares and the number of Equity Securities on issue or proposed to be issued as at 22 October 2026.</p> <p>The table also shows the voting dilution impact where the number of Shares on issue (Variable A in the formula) changes and the economic dilution where there are changes in the issue price of Shares issued under the 7.1A Mandate.</p> <table><tr><th colspan="2"></th><th colspan="4">DILUTION</th></tr><tr><th colspan="2" rowspan="4">Number of Shares on Issue (Variable A in Listing Rule 7.1A.2)</th><th rowspan="4">Shares issued – 10% voting dilution</th><th colspan="3">Issue Price</th></tr><tr><th>\$0.026</th><th>\$0.052</th><th>\$0.078</th></tr><tr><th>50% decrease</th><th>Issue Price</th><th>50% increase</th></tr><tr><th colspan="3">Funds Raised</th></tr><tr><td>Current</td><td>364,755,606 Shares</td><td>36,475,561 Shares</td><td>\$948,365</td><td>\$1,896,729</td><td>\$2,845,094</td></tr><tr><td>50% increase</td><td>547,133,409</td><td>54,713,341 Shares</td><td>\$1,422,547</td><td>\$2,845,094</td><td>\$4,267,641</td></tr><tr><td>100% increase</td><td>729,511,212</td><td>72,951,121 Shares</td><td>\$1,896,729</td><td>\$3,793,458</td><td>\$5,690,187</td></tr></table> <p>*The number of Shares on issue (Variable A in the formula) could increase as a result of the issue of Shares that do not require Shareholder approval (such as under a pro-rata rights issue or scrip issued under a takeover offer) or that are issued with Shareholder approval under Listing Rule 7.1.</p> <p>The table above uses the following assumptions:</p> <ol style="list-style-type: none">There are currently 364,755,606 existing Shares as at the date of this Notice.The issue price set out above is the closing market price of the Shares on the ASX on 22 October 2026 (being \$0.052) (Issue Price). The Issue Price at a 50% increase and 50% decrease are each rounded to three decimal places prior to the calculation of the funds raised.The Company issues the maximum possible number of Equity Securities under the 7.1A Mandate.			DILUTION				Number of Shares on Issue (Variable A in Listing Rule 7.1A.2)		Shares issued – 10% voting dilution	Issue Price			\$0.026	\$0.052	\$0.078	50% decrease	Issue Price	50% increase	Funds Raised			Current	364,755,606 Shares	36,475,561 Shares	\$948,365	\$1,896,729	\$2,845,094	50% increase	547,133,409	54,713,341 Shares	\$1,422,547	\$2,845,094	\$4,267,641	100% increase	729,511,212	72,951,121 Shares	\$1,896,729	\$3,793,458	\$5,690,187
		DILUTION																																						
Number of Shares on Issue (Variable A in Listing Rule 7.1A.2)		Shares issued – 10% voting dilution	Issue Price																																					
			\$0.026	\$0.052	\$0.078																																			
			50% decrease	Issue Price	50% increase																																			
			Funds Raised																																					
Current	364,755,606 Shares	36,475,561 Shares	\$948,365	\$1,896,729	\$2,845,094																																			
50% increase	547,133,409	54,713,341 Shares	\$1,422,547	\$2,845,094	\$4,267,641																																			
100% increase	729,511,212	72,951,121 Shares	\$1,896,729	\$3,793,458	\$5,690,187																																			

REQUIRED INFORMATION	DETAILS
	<p>4. The Company has not issued any Equity Securities in the 12 months prior to the Meeting that were not issued under an exception in Listing Rule 7.2 or with approval under Listing Rule 7.1.</p> <p>5. The issue of Equity Securities under the 7.1A Mandate consists only of Shares. It is assumed that no Options are exercised into Shares before the date of issue of the Equity Securities. If the issue of Equity Securities includes quoted Options, it is assumed that those quoted Options are exercised into Shares for the purpose of calculating the voting dilution effect on existing Shareholders.</p> <p>6. The calculations above do not show the dilution that any one particular Shareholder will be subject to. All Shareholders should consider the dilution caused to their own shareholding depending on their specific circumstances.</p> <p>7. This table does not set out any dilution pursuant to approvals under Listing Rule 7.1 unless otherwise disclosed.</p> <p>8. The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%.</p> <p>9. The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 7.1A Mandate, based on that Shareholder's holding at the date of the Meeting.</p> <p>Shareholders should note that there is a risk that:</p> <p>(a) the market price for the Company's Shares may be significantly lower on the issue date than on the date of the Meeting; and</p> <p>(b) the Shares may be issued at a price that is at a discount to the market price for those Shares on the date of issue.</p>
<p>Allocation policy under 7.1A Mandate</p>	<p>The recipients of the Equity Securities to be issued under the 7.1A Mandate have not yet been determined. However, the recipients of Equity Securities could consist of current Shareholders or new investors (or both), none of whom will be related parties of the Company.</p> <p>The Company will determine the recipients at the time of the issue under the 7.1A Mandate, having regard to the following factors:</p> <p>(a) the purpose of the issue;</p> <p>(b) alternative methods for raising funds available to the Company at that time, including, but not limited to, an entitlement issue, share purchase plan, placement or other offer where existing Shareholders may participate;</p> <p>(c) the effect of the issue of the Equity Securities on the control of the Company;</p> <p>(d) the circumstances of the Company, including, but not limited to, the financial position and solvency of the Company;</p> <p>(e) prevailing market conditions; and</p> <p>(f) advice from corporate, financial and broking advisers (if applicable).</p>
<p>Previous approval under Listing Rule 7.1A.2</p>	<p>The Company previously obtained approval from its Shareholders pursuant to Listing Rule 7.1A at its annual general meeting held on 28 November 2025 (Previous Approval).</p> <p>During the 12-month period preceding the date of the Meeting, being on and from 25 November 2025, the</p>

REQUIRED INFORMATION	DETAILS										
	<p>Company issued 30,583,474 Shares pursuant to the Previous Approval (Previous Issue), which represent approximately 9% of the total diluted number of Equity Securities on issue in the Company on 25 November 2025, which was 341,348,144.</p> <p>Further details of the issues of Equity Securities by the Company pursuant to Listing Rule 7.1A.2 during the 12 month period preceding the date of the Meeting are set out below.</p> <p>The following information is provided in accordance with Listing Rule 7.3A.6(b) in respect of the Previous Issue:</p> <table border="1" data-bbox="662 589 1388 1697"> <tr> <td data-bbox="662 589 874 674">Date of Issue and Appendix 2A</td><td data-bbox="874 589 1388 674"> Date of Issue: 25 June 2026 Date of Appendix 2A: 25 and 26 June 2026 </td></tr> <tr> <td data-bbox="662 674 874 775">Number and Class of Equity Securities Issued</td><td data-bbox="874 674 1388 775">30,583,474 Shares²</td></tr> <tr> <td data-bbox="662 775 874 898">Issue Price and discount to Market Price¹ (if any)</td><td data-bbox="874 775 1388 898">\$0.115 per Share (at a premium of 22.34% to Market Price).</td></tr> <tr> <td data-bbox="662 898 874 1249">Recipients</td><td data-bbox="874 898 1388 1249"> Professional and sophisticated investors as part of a placement announced on 22 June 2026. The placement participants were identified through a bookbuild process, which involved the joint lead managers to the placement, Alpine Capital Pty Ltd and SP Corporate Advisory Pty Ltd, seeking expressions of interest to participate in the placement from non-related parties of the Company. None of the participants in the placement were material investors that are required to be disclosed under ASX Guidance Note 21. </td></tr> <tr> <td data-bbox="662 1249 874 1697">Total Cash Consideration and Use of Funds</td><td data-bbox="874 1249 1388 1697"> Amount raised: \$3,517,100 Amount spent: \$1,399,100 Use of funds: research and development , patents and patent renewals, part settlement of R&D funding facility with RiverFort Global Opportunities PCC Ltd, development of internal business systems and software tools, general working capital and the costs of the placement. Amount remaining: \$2,118,000 Proposed use of remaining funds:³ business improvement initiatives, research and development, patents and patent renewals and general working capital. </td></tr> </table> <p>Notes:</p> <ol style="list-style-type: none"> 1. Market Price means the closing price of Shares on ASX (excluding special crossings, overnight sales and exchange traded option exercises). For the purposes of this table the discount is calculated on the Market Price on the last trading day on which a sale was recorded prior to the date of issue of the relevant Equity Securities. 2. Fully paid ordinary shares in the capital of the Company, ASX Code: CPV (terms are set out in the Constitution). 3. This is a statement of current intentions as at the date of this Notice. As with any budget, intervening events and new circumstances have the potential to affect the manner in which the funds are ultimately applied. The Board reserves the right to alter the way the funds are applied on this basis. 	Date of Issue and Appendix 2A	Date of Issue: 25 June 2026 Date of Appendix 2A: 25 and 26 June 2026	Number and Class of Equity Securities Issued	30,583,474 Shares ²	Issue Price and discount to Market Price¹ (if any)	\$0.115 per Share (at a premium of 22.34% to Market Price).	Recipients	Professional and sophisticated investors as part of a placement announced on 22 June 2026. The placement participants were identified through a bookbuild process, which involved the joint lead managers to the placement, Alpine Capital Pty Ltd and SP Corporate Advisory Pty Ltd, seeking expressions of interest to participate in the placement from non-related parties of the Company. None of the participants in the placement were material investors that are required to be disclosed under ASX Guidance Note 21.	Total Cash Consideration and Use of Funds	Amount raised: \$3,517,100 Amount spent: \$1,399,100 Use of funds: research and development , patents and patent renewals, part settlement of R&D funding facility with RiverFort Global Opportunities PCC Ltd, development of internal business systems and software tools, general working capital and the costs of the placement. Amount remaining: \$2,118,000 Proposed use of remaining funds: ³ business improvement initiatives, research and development, patents and patent renewals and general working capital.
Date of Issue and Appendix 2A	Date of Issue: 25 June 2026 Date of Appendix 2A: 25 and 26 June 2026										
Number and Class of Equity Securities Issued	30,583,474 Shares ²										
Issue Price and discount to Market Price¹ (if any)	\$0.115 per Share (at a premium of 22.34% to Market Price).										
Recipients	Professional and sophisticated investors as part of a placement announced on 22 June 2026. The placement participants were identified through a bookbuild process, which involved the joint lead managers to the placement, Alpine Capital Pty Ltd and SP Corporate Advisory Pty Ltd, seeking expressions of interest to participate in the placement from non-related parties of the Company. None of the participants in the placement were material investors that are required to be disclosed under ASX Guidance Note 21.										
Total Cash Consideration and Use of Funds	Amount raised: \$3,517,100 Amount spent: \$1,399,100 Use of funds: research and development , patents and patent renewals, part settlement of R&D funding facility with RiverFort Global Opportunities PCC Ltd, development of internal business systems and software tools, general working capital and the costs of the placement. Amount remaining: \$2,118,000 Proposed use of remaining funds: ³ business improvement initiatives, research and development, patents and patent renewals and general working capital.										

REQUIRED INFORMATION	DETAILS
Voting exclusion statement	As at the date of this Notice, the Company is not proposing to make an issue of Equity Securities under Listing Rule 7.1A. Accordingly, a voting exclusion statement is not included in this Notice.

6. RESOLUTION 5 – INCREASE IN TOTAL AGGREGATE REMUNERATION FOR NON-EXECUTIVE DIRECTORS

6.1 General

This Resolution seeks Shareholder approval for the purposes of clause 15.8 of the Constitution and Listing Rule 10.17 to increase the total aggregate amount of fees payable to non-executive Directors from \$350,000 per annum to \$450,000 per annum.

Listing Rule 10.17 provides that an entity must not increase the total aggregate amount of directors' fees payable to all of its non-executive directors without the approval of holders of its ordinary securities.

Directors' fees include all fees payable by the entity or any of its child entities to a non-executive director for acting as a director of the entity or any of its child entities (including attending and participating in any board committee meetings), superannuation contributions for the benefit of a non-executive director and any fees which a non-executive director agrees to sacrifice for other benefits. It does not include reimbursement of genuine out of pocket expenses, genuine "special exertion" fees paid in accordance with an entity's constitution, or securities issued to a non-executive director under Listing Rules 10.11 or 10.14 with the approval of the holders of its ordinary securities.

Clauses 15.7 and 15.8 of the Constitution provide that total aggregate remuneration payable to the non-executive Directors will not exceed the sum initially set by the Constitution and subsequently increased by ordinary resolution of Shareholders in a general meeting.

6.2 Technical information required by Listing Rule 14.1A

If this Resolution is passed, the maximum aggregate amount of fees payable to the non-executive Directors will increase by \$100,000 to \$450,000.

If this Resolution is not passed, the maximum aggregate amount of fees payable to non-executive Directors will remain at \$350,000. This may inhibit the ability of the Company to remunerate, attract and retain appropriately skilled non-executive directors.

6.3 Technical information required by Listing Rule 10.17

REQUIRED INFORMATION	DETAILS
Maximum aggregate amount of directors' fees	<p>This Resolution seeks to increase the maximum aggregate amount of fees payable to the non-executive Directors by an amount of \$100,000 to \$450,000 per annum.</p> <p>This amount has been determined after reviewing similar companies listed on ASX and the Directors believe that this level of remuneration is in line with corporate remuneration of similar companies.</p> <p>Whilst it is not envisaged that the maximum amount sought will be utilised immediately, the increase to maximum aggregate amount of fees payable may enable the Company to:</p> <ul style="list-style-type: none"> (a) fairly remunerate both existing and any new non-executive directors joining the Board; (b) remunerate its non-executive Directors appropriately for the expectations placed upon them both by the Company and the regulatory environment in which it operates; and

REQUIRED INFORMATION	DETAILS
	(c) have the ability to attract and retain non-executive directors whose skills and qualifications are appropriate for a company of the size and nature of the Company.
Securities issued to non-executive Directors	<p>In the past 3 years, the Company has issued an aggregate of 1,238,864 Shares, 3,086,667 Options and 3,000,000 Performance Rights to non-executive Directors pursuant to Listing Rules 10.11 and 10.14, as follows:</p> <p>(a) 1,000,000 Options were issued to each of Gerd Hoenicke, Victor Rosenberg and Charles Mowrey on 13 December 2023 pursuant to Listing Rule 10.11;</p> <p>(b) 20,000 Options were issued to Victor Rosenberg on 19 June 2024 pursuant to a share purchase plan under Listing Rule 10.11;</p> <p>(c) 200,000 Shares and 66,667 Options were issued to Charles Mowrey on 19 June 2024 pursuant to a placement under Listing Rule 10.11;</p> <p>(d) 1,500,000 Performance Rights were issued to each of Theresa Smits and Michael Pixley pursuant to Listing Rule 10.11;</p> <p>(e) 288,864 Shares were issued to Theresa Smits under the Fee Plan on 6 January 2026 under Listing Rule 10.14;</p> <p>(f) 750,000 Shares and 750,000 Options were issued to Theresa Smits on 22 October 2026 pursuant to a placement under Listing Rule 10.11.</p>
Voting exclusion statement	A voting exclusion statement applies to this Resolution.
Voting prohibition statement	A voting prohibition statement applies to this Resolution.

6.4 Board Recommendation

Given the interest of the non-executive Directors in this Resolution, the Board makes no recommendation to Shareholders regarding this Resolution.

7. RESOLUTION 6 – APPROVAL TO ISSUE SHARES UNDER THE DIRECTOR FEE PLAN – THERESA SMITS

7.1 Background

The Company has adopted a Director Fee Plan (**Fee Plan**) to enable the Company to issue Shares to Directors in lieu of accrued cash remuneration. Eligible participants are directors of the Company or any related entity or any nominee of such parties. Under the Fee Plan, eligible participants can elect to be paid some or all of the cash remuneration accrued to them by the issue of Shares. Any issues of Shares then made are at the discretion of the Board.

The objective of the Fee Plan is to give the Company a cost effective means of remunerating its Directors which aligns the interests of the Board with Shareholders and incentivises such parties (with the number of Shares to be issued in lieu of remuneration being directly linked to the performance of the Company's Share price) and allows the Company to allocate a greater proportion of its cash reserves to advancing its business.

The Company must seek Shareholder approval under Listing Rule 10.14 in respect of any issues of Shares under the Fee Plan to a related party or a person whose relationship with the Company or the related party is, in ASX' s opinion, such that approval should be obtained.

At the Company's annual general meeting held on 28 November 2025, Shareholders approved the issue of Shares under the Fee Plan to Theresa Smits in lieu of directors' fees for the period up to 27 November 2026.

7.2 General

The Company has agreed, subject to obtaining Shareholder approval, to issue Shares in lieu of remuneration to Theresa Smits (or her nominee(s)) pursuant to the Fee Plan and on the terms and conditions set out below.

The issue of Shares to Ms Smits in lieu of accrued cash payments for remuneration under the terms of the Fee Plan will allow the Company to maintain its cash reserves to the extent of participation in the Fee Plan.

Under the Fee Plan, Ms Smits may elect to be paid a portion of the cash remuneration accrued to her (as set out below) by the issue of Shares on a monthly or quarterly basis. An election can be made by Ms Smits for each calendar month within 5 business days after the end of that calendar month. The Shares will be issued in lieu of cash due to the Director and thereby no funds will be raised as a result of the issue of the Shares. A summary of the terms of the Fee Plan is set out in Schedule 1.

The number of Shares to be issued to Theresa Smits will be determined by the Board based on each portion of the Director's fees payable by the Company for the relevant calendar month at the time an offer is made, divided by the relevant issue price set out in the table below (which will be the volume weighted average price (**VWAP**) of the Company's Shares trading on ASX over the relevant calendar month from 25 November 2026 to 24 November 2027).

While Listing Rule 10.15.7 allows an entity to seek Shareholder approval to issue Securities under an employee incentive scheme up to 3 years from the date of Shareholder approval, the Company is seeking Shareholder approval pursuant to this Resolution to issue Shares under the Fee Plan for a period of only 12 months from the date of the Meeting.

The maximum number of Shares that Theresa Smits can receive in the 12 month period from 25 November 2026 to 24 November 2027 will be determined by the percentage of remuneration for that period which is sacrificed and satisfied by the issue of Shares and the issue price for the relevant period, as set out below.

While the maximum number of Shares to be issued for such 12 month period cannot yet be determined, set out below are some examples of the number of Shares that may be issued to Theresa Smits under the Fee Plan over this period, based on an assumed price of \$0.052 per Share (being the closing market price on 22 October 2026). These are examples only and Shareholders should be aware that the actual number of Shares to be issued to Ms Smits may vary, based on the prevailing Share price at the time the number of Shares to be issued is to be calculated, and the percentage of remuneration Ms Smits elects to sacrifice. The maximum amount of cash remuneration which can be sacrificed by the issue of Shares to Ms Smits over the 12 month period from the date of the Meeting is \$120,000.

Based on Ms Smits sacrificing 100% of her Director fees and a Share price of \$0.052 per Share, Ms Smits would be issued with approximately the number of Shares detailed in the table below for the 12 month period from the date of the Meeting.

ROLE/PERIOD	ACCRUED REMUNERATION (\$)	ISSUE PRICE	SHARES TO BE ISSUED
Chair (25 November 2026 – 24 November 2027)	\$120,000	\$0.052 (being the assumed VWAP for the purposes of this calculation)	2,307,692

This would dilute current Shareholders by the percentage set out below based on the Company's current share capital:

NUMBER OF SHARES CURRENTLY ON ISSUE (AT THE DATE OF THIS NOTICE)	NUMBER OF SHARES TO BE ISSUED TO THERESA SMITS UNDER FEE PLAN	DILUTION
364,755,606	2,307,692	0.63%

7.3 Director Recommendation

The Directors (other than Theresa Smits) recommend that Shareholders vote in favour of this Resolution for the reasons set out in Section 7.7 below. In forming their recommendation, the Directors (other than Theresa Smits) considered the experience of Theresa Smits, the current market price of Shares and the current market standards and practices when determining the number Shares to be issued. Theresa Smits has a material personal interest in the outcome of this Resolution on the basis that she is to be issued Shares should the Resolution be passed. For this reason, Theresa Smits does not believe that it is appropriate to make a recommendation on this Resolution.

7.4 Chapter 2E of the Corporations Act

Chapter 2E of the Corporations Act requires that for a public company, or an entity that the public company controls, to give a financial benefit to a related party of the public company, the public company or entity must:

- (a) obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and
- (b) give the benefit within 15 months following such approval,

unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.

The issue of Shares under the Fee Plan constitutes giving a financial benefit and Ms Smits is a related party of the Company by virtue of being a Director.

The Directors (other than Theresa Smits who has a material personal interest in the Resolution) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of the issue because the agreement to issue the Shares under the Fee Plan reached as part of the remuneration package for Ms Smits is considered reasonable remuneration in the circumstances and was negotiated on an arm's length basis.

7.5 Listing Rule 10.14

Listing Rule 10.14 provides that an entity must not permit any of the following persons to acquire equity securities under an employee incentive scheme without the approval of the holders of its ordinary securities:

- (a) a director of the entity (Listing Rule 10.14.1);
- (b) an associate of a director of the entity (Listing Rule 10.14.2); or
- (c) a person whose relationship with the entity or a person referred to in Listing Rules 10.14.1 to 10.14.2 is such that, in ASX's opinion, the acquisition should be approved by security holders (Listing Rule 10.14.3).

The issue falls within Listing Rule 10.14.1 and therefore requires the approval of Shareholders under Listing Rule 10.14.

7.6 Technical information required by Listing Rule 14.1A

If this Resolution is passed, the Company will be able to proceed with the issue of the Shares to Ms Smits under the Fee Plan within 15 months after the date of the Meeting. As approval pursuant to Listing Rule 7.1 is not required for the issue (because approval is being obtained under Listing Rule 10.14), the issue will not use up any of the Company's 15% annual placement capacity.

If this Resolution is not passed, the Company will not be able to proceed with the issue of the Shares to Ms Smits under the Fee Plan and the Company will be required to pay Ms Smits' Directors' fees in cash.

REQUIRED INFORMATION	DETAILS
Name of the persons to whom Securities will be issued	Theresa Smits (or her nominee(s)).
Categorisation under Listing Rule 10.14	<p>Ms Smits falls within the category set out in Listing Rule 10.14.1 as she is a related party of the Company by virtue of being a Director.</p> <p>Any nominee(s) of Ms Smits who receive Securities may constitute 'associates' for the purposes of Listing Rule 10.14.2.</p>
Number of Securities and class to be issued	The maximum number of Shares to be issued to Ms Smits under the Fee Plan for each calendar month will be equal to the amount of the Director fees elected to be sacrificed for such period divided by the VWAP of the Shares over the relevant calendar month as shown in the example set out in Section 7.2 above.
Remuneration package	The current total remuneration package for Theresa Smits (including superannuation, but excluding any discretionary bonuses and any non-cash or equity benefits) is \$120,000.
Securities previously issued to the recipients under the Fee Plan	288,864 Shares have previously been issued to Theresa Smits under the Fee Plan, at a deemed issue price of \$0.14 per Share, in lieu of Directors' fees.
Terms of Securities	The Shares will be fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares.
Consideration of type of Security to be issued	<p>The Company has agreed to issue the Shares for the following reasons:</p> <ul style="list-style-type: none"> (a) the issue to the Ms Smits will align the interests of the recipient with those of Shareholders; (b) the issue is a reasonable and appropriate method to provide cost effective remuneration as the non-cash form of this benefit will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to Ms Smits; and (c) it is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing the Shares on the terms proposed.
Valuation	The Shares issued under the Fee Plan in lieu of accrued Directors' fees will be issued at a cost equal to the value of Ms Smits' Director fees that would otherwise be payable by the Company in cash (as set out in the table in Section 7.2).
Date(s) on or by which the Securities will be issued	The Company will not issue any Shares under the Fee Plan later than 15 months after the date of the Meeting.
Issue price of Securities	The Shares will be issued for nil cash consideration in lieu of Directors' fees, at a deemed issue price equal to the VWAP of the Shares over the calendar month to which the relevant Directors' fees relate. No funds will be raised from the issue.

REQUIRED INFORMATION	DETAILS
Purpose of the issue, including the intended use of any funds raised by the issue	The Company is seeking Shareholder approval for the issue of Shares to Theresa Smits under the Fee Plan in order that the Company has flexibility to issue Shares to Theresa Smits in lieu of accrued cash payments for remuneration which will allow the Company to maintain its cash reserves.
Material terms of the Plan	A summary of the material terms and conditions of the Fee Plan is set out in Schedule 1.
Material terms of any loan	No loan is being made in connection with the acquisition of the Securities.
Additional Information	<p>Details of any Securities issued under the Fee Plan will be published in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14.</p> <p>Any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of Securities under the Fee Plan after this Resolution is approved and who were not named in this Notice will not participate until approval is obtained under Listing Rule 10.14.</p>
Voting exclusion statement	A voting exclusion statement applies to this Resolution.
Voting prohibition statement	A voting prohibition statement applies to this Resolution.

GLOSSARY

\$ means Australian dollars.

7.1A Mandate has the meaning given in Section 5.1.

ASIC means the Australian Securities & Investments Commission.

ASX means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.

Board means the current board of directors of the Company.

Chair means the chair of the Meeting.

Closely Related Party of a member of the Key Management Personnel means:

- (a) a spouse or child of the member;
- (b) a child of the member's spouse;
- (c) a dependent of the member or the member's spouse;
- (d) anyone else who is one of the member's family and may be expected to influence the member, or be influenced by the member, in the member's dealing with the entity;
- (e) a company the member controls; or
- (f) a person prescribed by the Corporations Regulations 2001 (Cth) for the purposes of the definition of 'closely related party' in the Corporations Act.

Company means ClearVue Technologies Limited (ACN 071 397 487).

Constitution means the Company's constitution.

Corporations Act means the *Corporations Act 2001* (Cth).

Directors means the current directors of the Company.

Eligible Entity means an entity which is not included in the S&P/ASX 300 Index and has a market capitalisation of \$300,000,000 or less.

Equity Securities includes a Share, a right to a Share or Option, an Option, a convertible security and any security that ASX decides to classify as an Equity Security.

Explanatory Statement means the explanatory statement accompanying the Notice.

Fee Plan means the Company's Director Fee Plan, a summary of the material terms of which is set out in Schedule 1.

Key Management Personnel has the same meaning as in the accounting standards issued by the Australian Accounting Standards Board and means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, or if the Company is part of a consolidated entity, of the consolidated entity, directly or indirectly, including any director (whether executive or otherwise) of the Company, or if the Company is part of a consolidated entity, of an entity within the consolidated group.

Listing Rules means the Listing Rules of ASX.

Meeting means the meeting convened by the Notice.

Notice means this notice of meeting including the Explanatory Statement and the Proxy Form.

Option means an option to acquire a Share.

Performance Right means a right to acquire a Share subject to satisfaction of performance milestones.

Proxy Form means the proxy form accompanying the Notice.

Remuneration Report means the remuneration report set out in the Directors' report section of the Company's annual financial report for the year ended 30 June 2026.

Resolutions means the resolutions set out in the Notice, or any one of them, as the context requires.

Section means a section of the Explanatory Statement.

Security means a Share, Option or Performance Right (as applicable).

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a registered holder of a Share.

Variable A means “A” as set out in the formula in Listing Rule 7.1A.2.

VWAP has the meaning given in Section 7.2.

WST means Western Standard Time as observed in Perth, Western Australia.

SCHEDULE 1 – TERMS AND CONDITIONS OF DIRECTOR FEE PLAN

1. All executive and non-executive directors of the Company (**Participants**) and any related entity and any nominee of such parties shall be entitled during the term of the Fee Plan (**Plan**) to elect by notice in writing to the Company (**Election Notice**) to be paid some or all of the remuneration due and owing to them by the Company from time to time as fees for services (**Outstanding Remuneration**) by way of an issue of Shares (**Plan Shares**).
2. Subject to paragraph 3, an Election Notice may be given by a Participant at any time (including prior to a calendar month's end) provided it is given no later than 5 business days after the end of such calendar month during the Plan and shall specify:
 - (a) the amount of any Outstanding Remuneration that a Participant wishes to be paid by way of Plan Shares under the Plan; and
 - (b) whether the Participant wishes to have the Plan Shares issued in his or her own name or in the name of a nominee (**Recipient**).
3. An Election Notice may be given to the Company in any manner permitted under the Constitution for service by the Company of notices.
4. Upon receipt of an Election Notice, Plan Shares may be issued to each Participant who elects to be issued Plan Shares in lieu of any Outstanding Remuneration at the discretion of the Board.
5. For Participants who give an Election Notice for a relevant calendar month, the deemed issue price of Plan Shares to be issued under such Election Notice will be equal to the volume weighted average price for Shares calculated over the relevant calendar month.
6. Any fractional entitlement to be issued in respect of the Plan Shares shall be rounded down to the nearest whole number.
7. The Company shall:
 - (a) issue the Plan Shares to a Recipient as soon as practicable after conclusion of the calendar month or quarter to which the Outstanding Remuneration relates;
 - (b) forthwith deliver a holding statement to the Recipient in respect of the Plan Shares; and
 - (c) cause the Plan Shares to be listed on ASX as soon as reasonably practicable at the Company's cost and expense.
8. The obligation of the Company to issue any Plan Shares is subject to the receipt of any approvals required under:
 - (a) the Listing Rules; and
 - (b) the Corporations Act.
9. Notwithstanding any other provision of the Plan, a Participant may only receive the number of Plan Shares as approved by shareholders of the Company under the ASX Listing Rules and the Corporations Act.

Proxy Voting Form

If you are attending the Meeting in person, please bring this with you for Securityholder registration.

Your proxy voting instruction must be received by **2:00pm (AWST) on Wednesday, 25 November 2026**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automicgroup.com.au>.

Lodging your Proxy Voting Form:

Online

Use your computer or smartphone to appoint a proxy at <https://portal.automic.com.au/investor/home> or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBSITE:

<https://automicgroup.com.au>

PHONE:

1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

